Summit Biosciences expansion nearing completion

Nasal spray CDMO Summit Biosciences has nearly completed a $19 million expansion of its facility at the University of Kentucky Coldstream Research Campus that is expected to create 78 jobs, the state of Kentucky has announced. Following the expansion, which includes laboratory, warehouse, and manufacturing space, the facility will total 44,000 sq ft.

The company, which currently employs 125 people, has been granted up to $1.5 million in tax incentives based on the investment and on creating and maintaining the 78 positions for 10 years at an average pay rate of $28/hour.

In May 2020, Atossa Therapeutics announced that Summit would provide development and manufacturing services for Atossa’s AT-301 nasal spray for the treatment and possible prevention of COVID-19.

Summit President and Chief Operating Officer Greg Plucinski commented, “We are excited and honored to have been entrusted by Atossa Therapeutics to aid in the development of a product that could potentially be used in the global fight against the coronavirus. Our dedicated, high-performing team has taken this immense responsibility and worked extremely hard to deliver products for the start of human clinical studies in record time.”

Read the Kentucky press release.

Share

published on

November 10-November 11: Rescon Europe 2026, Porto, Portugal

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

June 30: RespireX 2027, Boston, MA, USA